Gender Solutions Natural Knee Post-Market Study

Sponsor
Zimmer Biomet (Industry)
Overall Status
Withdrawn
CT.gov ID
NCT01463566
Collaborator
(none)
0
156

Study Details

Study Description

Brief Summary

This is a prospective multicenter study of the Gender Solutions Natural Knee Flex System when used in primary total knee arthroplasty. The purpose of the study is to obtain short-, Mid-, and long-term clinical outcomes and implant survivorship data for the Gender Solutions Natural Knee Flex System.

Condition or Disease Intervention/Treatment Phase
  • Device: Zimmer Gender(R) Solutions(TM) Natural-Knee(R) Flex System

Detailed Description

Survival and outcome data on the Gender Solutions Natural Knee Flex System will be done by an analysis of standard scoring system, radiographs and adverse event records. Survivorship will be evaluated by monitoring the frequency and incidence of adverse events, serious adverse events, adverse device effects, serious adverse device effects, and unanticipated adverse device effects. Outcomes will be measured by comparing the overall pain and function performances (based on the Knee Society Scoring System), survivorship, subject quality of life and radiographic parameters of study subjects receiving the Gender Solutions Natural Knee Flex System.

Study Design

Study Type:
Observational
Actual Enrollment :
0 participants
Observational Model:
Case-Only
Time Perspective:
Prospective
Official Title:
Prospective Multicenter Post-market Study of the Zimmer Gender Solutions Natural Knee Flex System
Study Start Date :
Jan 1, 2012
Anticipated Primary Completion Date :
Jul 1, 2024
Anticipated Study Completion Date :
Jan 1, 2025

Arms and Interventions

Arm Intervention/Treatment
1 - Gender Natural Knee

Patients suffering from severe knee pain and disability.

Device: Zimmer Gender(R) Solutions(TM) Natural-Knee(R) Flex System
Gender Solutions Natural Knee Flex System in total knee arthroplasty

Outcome Measures

Primary Outcome Measures

  1. Survivorship [10 years]

    Based on frequency of adverse events, serious adverse events, adverse device effects, serious adverse devices effects and unanticipated adverse device effects or removal of the device summarized using a Kaplan-Meier method and presented with rates (as percentages) and confidence intervals.

Secondary Outcome Measures

  1. Pain Performance [10 years]

    Measured by comparing the overall pain performances (based on Knee Society Scoring System), Survivorship, subject quality of life and radiographic parameters.

  2. Function Performance [10 Years]

    Measured by comparing the overall function performances (based on the Knee Society Scoring System), survivorship, subject quality of life and radiographic parameters.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 75 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Patient 18-75 years of age, inclusive;

  • Patient qualifies for a total knee arthroplasty based on physical exam and medical history including at least one of the following: osteoarthritis, inflammatory arthritis, post-traumatic arthritis, rheumatoid arthritis, or valgus, varus, or flexion deformities;

  • Patient has undergone a study related informed consent process;

  • Patient is willing and able to provide written consent;

  • Patient is willing and able to cooperate in the required post-operative therapy;

  • Patient is willing and able to complete scheduled follow-up evaluations.

Exclusion Criteria:
  • Patient has previous history of infection in the affected joint and/or a local or systemic infection that could affect the prosthetic joint;

  • Insufficient bone stock on femoral or tibial surfaces;

  • Skeletal immaturity

  • Neuropathic arthropathy

  • Osteoporosis or any loss of musculature or neuromuscular disease that compromises the affected limb;

  • Stable, painless arthrodesis in a satisfactory functional position;

  • Severe instability secondary to the absence of collateral ligament integrity;

  • Patient has rheumatoid arthritis and an ulcer of the skin or a history of recurrent breakdown of the skin because of their risk of postoperative infection is greater;

  • Patient has known sensitivity or allergy to one or more of the implanted materials;

  • Patients pregnant or considered a member of a protected population (e.g., prisoner, mental incompetence, unable to understand what clinical trial participation entails, etc.)

Contacts and Locations

Locations

No locations specified.

Sponsors and Collaborators

  • Zimmer Biomet

Investigators

  • Study Director: Kacy Arnold, RN, MBA, Zimmer Biomet

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Zimmer Biomet
ClinicalTrials.gov Identifier:
NCT01463566
Other Study ID Numbers:
  • CMU2011-05K
First Posted:
Nov 2, 2011
Last Update Posted:
Jan 9, 2019
Last Verified:
Jan 1, 2019
Keywords provided by Zimmer Biomet
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jan 9, 2019